EUVIMEDEUVIMED entdecken
Crossref

The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients

Wenwen Qin, Cuimin Ding, Fei Peng, Ping Wang

Annales de Biologie Clinique · 2023

DOI: 10.1684/abc.2023.1861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales de Biologie Clinique, 2023. Verfasst von Wenwen Qin und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to evaluate the mRNA levels of solute carrier family 22, member 17 (SLC22A17) and its potential clinical value as a diagnostic and prognostic biomarker in non-small cell lung cancer. This prospective study measured SLC22A17 mRNA levels in lung cancer and paracancer tissues using quantitative reverse transcription-polymerase chain reaction (PCR). The levels of SLC22A17 mRNA in plasma samples from healthy control subjects and patients with lung cancer were also measured. The association between SLC22A17 mRNA levels in plasma and clinicopathological characteristics was determined. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic value of SLC22A17 in plasma. Survival curve analysis was performed using the Kaplan-Meier method. SLC22A17 mRNA levels were significantly higher in lung cancer samples than in the paired paracancerous tissues. Plasma SLC22A17 mRNA levels were also significantly higher in patients with lung cancer than in healthy controls. The COX analysis indicated that there was a significant correlation between elevated plasma SLC22A17 mRNA levels and lymph node metastasis, distant metastasis, and TNM stage. Furthermore, the ROC curve analysis demonstrated that plasma SLC22A17 had high diagnostic value. High plasma SLC22A17 mRNA levels are associated with a significantly shorter survival time. SLC22A17 is upregulated in lung cancer and may serve as a novel diagnostic and prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPrognosisRNA, MessengerProspective StudiesROC CurveBiomarkersBiomarkers, TumorOrganic Cation Transport Proteins

Stichwörter der Autor:innen

SLC22A17biomarkerlung cancer tissuesprognosis

Substanzen

RNA, MessengerBiomarkersBiomarkers, TumorSLC22A17 protein, humanOrganic Cation Transport Proteins

Zitieren

APA

Qin, W., Ding, C., Peng, F., & Wang, P. (2023). The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients. Annales de Biologie Clinique. https://doi.org/10.1684/abc.2023.1861

Vancouver

Qin W, Ding C, Peng F, Wang P. The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients. Annales de Biologie Clinique. 2023. doi:10.1684/abc.2023.1861

BibTeX
@article{Qin2023,
  author = {Qin, Wenwen and Ding, Cuimin and Peng, Fei and Wang, Ping},
  title = {The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients},
  journal = {Annales de Biologie Clinique},
  year = {2023},
  doi = {10.1684/abc.2023.1861}
}
Kostenlos starten →